CTLA4 and melanoma: Combination treatment of both anti-PD-1 and anti-CTLA4 antibodies resulted in a more severe hepatotoxicity: 17.6–21% for all grades and 8.3–11% for grade 3/4 toxicity in patients treated for melanoma [37].